|
Michael Raab joined NEA in June 2002 and specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab was most recently Senior Vice President, Therapeutics and General Manager, Renagel at Genzyme Corporation where he turned Renagel into a $1 billion opportunity. Prior to that, he was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of new therapeutic product opportunities. Mr. Raab gained extensive international experience while building a commercial operation in Latin American for the Therapeutics and Surgical Products groups for the company. Mr. Raab was also Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme's $600 million therapies for Gaucher Disease, and spent two years with Genzyme's Diagnostic Products and Services Division. Previous to Genzyme, Mr. Raab held sales and marketing positions at Repligen and Bristol-Myers. He received a Bachelor of Arts from DePauw University. | 